Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005;2(1):50-57.
doi: 10.7150/ijms.2.50. Epub 2005 Jan 5.

Epidemiology and Prevention of Hepatitis B Virus Infection

Affiliations

Epidemiology and Prevention of Hepatitis B Virus Infection

Jinlin Hou et al. Int J Med Sci. 2005.

Abstract

Hepatitis B is one of the most common infectious diseases globally. It has been estimated that there are 350 million chronic hepatitis B virus (HBV) carriers worldwide. The prevalence of chronic HBV infection varies geographically, from high (>8%), intermediate (2-7%) to low (<2%) prevalence. HBeAg-negative chronic hepatitis B (e-CHB) and occult HBV infection are two special clinical entities, and the prevalence and clinical implications remain to be explored. The predominant routes of transmission vary according to the endemicity of the HBV infection. In areas with high HBV endemicity, perinatal transmission is the main route of transmission, whereas in areas with low HBV endemicity, sexual contact amongst high-risk adults is the predominant route. HBV has been classified into 7 genotypes, i.e. A to G, based on the divergence of entire genome sequence and HBV genotypes have distinct geographical distributions. Three main strategies have been approved to be effective in preventing HBV infection. They are behavior modification, passive immunoprophylaxis, and active immunization. The implement of mass HBV immunization program is recommended by the WHO since 1991, and has dramatically decreased the prevalence of HBV infection and HCC in many countries.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Dr. Hou has received clinical research support from Roche, Bristol-Myers Squibb, Novartis, and GlaxoSmithKline. Others: none declared.

Figures

Figure 1
Figure 1
Geographic distribution of chronic hepatitis B infection, shown as HBsAg prevalence. Source of Figure: available on request from D. Lavanchy, World Health Organization, Communicable Diseases Surveillance and Response (CSR).

References

    1. Hepatitis B: World Health Organization Fact Sheet 204. World Health Organization; [2000]. http://www.who.int/mediacentre/factsheets/fs204/en/
    1. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut. 1996;38(suppl 2):S18–S23. - PMC - PubMed
    1. Lok AS. Chronic hepatitis B. N Engl J Med. 2002;346:1682–1683. - PubMed
    1. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev. 1999;12:351–366. - PMC - PubMed
    1. Lee WM. Hepatitis B infection. N Engl J Med. 1997;337:1733–1745. - PubMed